Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18007575 | 0.87 | HSD17B10 (0.72) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL2718887 | 0.79 | HSD17B10 (0.42) | HSD17B10KDM4E | |
| SCHEMBL19051434 | 0.79 | HSD17B10 (0.42) | HSD17B10HRH4KDM4E | |
| SCHEMBL15429553 | 0.79 | HSP90AA1 (0.67) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL24971324 | 0.79 | HSD17B10 (0.39) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL29566785 | 0.77 | HSD17B10 (0.55) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL5748941 | 0.77 | HSD17B10 (0.55) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL3188969 | 0.77 | HSD17B10 (0.55) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL179446 | 0.77 | HSD17B10 (0.55) | HSD17B10HRH4HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL179341 | 0.77 | HRH4 (0.46) | HSD17B10HRH4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-16 | — | — | US | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200268741-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-9006281-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8969377-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | RICE KENNETH D (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130274285-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC | 2013-10-17 | — | — | US | disclosed |
| US-8541448-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274285-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A2, SLC10A1, SLC9A2 | HSD17B10 1408/4885HRH4 164/4885HSP90AA1 475/4885 |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HSD17B10 1990/4885HRH4 2079/4885HSP90AA1 1707/4885 |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | SLC9A1, SLC9A2, SLC10A2 | HSD17B10 2030/4885HRH4 13/4885HSP90AA1 1827/4885 |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | HSD17B10 2879/4885HRH4 942/4885HSP90AA1 4038/4885 |
| US-20160067242-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HSD17B10 2335/4885HRH4 1453/4885HSP90AA1 954/4885 |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | HSD17B10 623/4885HRH4 472/4885HSP90AA1 150/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HSD17B10 1990/4885HRH4 2079/4885HSP90AA1 1707/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | HSD17B10 783/4885HRH4 282/4885HSP90AA1 235/4885 |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A2, SLC9A1, SLC9A2 | HSD17B10 1500/4885HRH4 14/4885HSP90AA1 1749/4885 |
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RPTOR, RICTOR | HSD17B10 3728/4885HRH4 1226/4885HSP90AA1 2696/4885 |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HSD17B10 2335/4885HRH4 1453/4885HSP90AA1 954/4885 |
| US-20200268741-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | HSD17B10 783/4885HRH4 282/4885HSP90AA1 235/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | HSD17B10 2879/4885HRH4 942/4885HSP90AA1 4038/4885 |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HSD17B10 2335/4885HRH4 1453/4885HSP90AA1 954/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | HSD17B10 783/4885HRH4 282/4885HSP90AA1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.